Subscribe
shutterstock_1335808664_nitpicker
nitpicker / Shutterstock.com
30 May 2019Big Pharma

Boehringer teams up with Gubra to develop second obesity treatment

German pharmaceutical company Boehringer Ingelheim has entered into a second licence and collaboration agreement with Danish biotech company Gubra for the development of an obesity treatment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Clean sweep for AbbVie in Humira litigation
15 May 2019   Boehringer Ingelheim has become the latest biosimilar maker to resolve litigation over AbbVie’s arthritis treatment Humira.
Americas
Boehringer Ingelheim teams up with IBM to explore blockchain
13 February 2019   The Canadian units of IBM and pharmaceutical company Boehringer Ingelheim have united to explore the use of blockchain technology in clinical trials.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Clean sweep for AbbVie in Humira litigation
15 May 2019   Boehringer Ingelheim has become the latest biosimilar maker to resolve litigation over AbbVie’s arthritis treatment Humira.
Americas
Boehringer Ingelheim teams up with IBM to explore blockchain
13 February 2019   The Canadian units of IBM and pharmaceutical company Boehringer Ingelheim have united to explore the use of blockchain technology in clinical trials.

More on this story

Americas
Clean sweep for AbbVie in Humira litigation
15 May 2019   Boehringer Ingelheim has become the latest biosimilar maker to resolve litigation over AbbVie’s arthritis treatment Humira.
Americas
Boehringer Ingelheim teams up with IBM to explore blockchain
13 February 2019   The Canadian units of IBM and pharmaceutical company Boehringer Ingelheim have united to explore the use of blockchain technology in clinical trials.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB